The 2017 ACC/AHA guidelines, chaired by Dr. Paul Whelton (Tulane University), redefined hypertension as 130/80 mmHg, adding approximately 31 million Americans to the hypertensive category. The SPRINT trial (n=9,361, NEJM 2015) was the pivotal evidence: targeting systolic below 120 mmHg reduced cardiovascular events by 25% and mortality by 27% compared to the standard 140 target.
The DASH diet remains the strongest dietary intervention. The original DASH trial (n=459, led by Dr. Lawrence Appel at Johns Hopkins) reduced systolic blood pressure by 5.5 mmHg versus a typical American diet, and by 11.4 mmHg in participants with hypertension. The DASH-Sodium follow-up showed that combining DASH with sodium restriction below 1,500 mg/day produced reductions of up to 20 mmHg, rivaling single-drug therapy.
Aerobic exercise produces consistent blood pressure reductions: 150 minutes per week of moderate-intensity activity lowers systolic BP by 5-8 mmHg. But the isometric finding is the surprise. Wall sits and isometric handgrip exercises, held for two minutes with one-minute rest intervals, three sessions per week, produced the largest effect sizes in the Edwards analysis.
Weight loss produces approximately 1 mmHg reduction in systolic blood pressure per kilogram lost. The Look AHEAD trial (n=5,145) demonstrated that modest weight loss of 5-10% body weight produces clinically meaningful improvements even without reaching normal BMI.
Alcohol reduction and potassium optimization are the most underutilized interventions. A 2023 JAMA Network Open meta-analysis (k=34, n=2,661, led by Dr. Marco Vinceti at University of Modena) confirmed that reducing alcohol from two or more drinks daily to one or fewer produces a 3.9 mmHg systolic reduction within weeks. The WHO's 2023 sodium-potassium guideline recommends 3,500 mg/day of potassium, which most Americans fall 1,000 mg short of.
When to pursue medication: the AHA recommends pharmacotherapy for persistent blood pressure above 140/90 despite three to six months of sustained lifestyle modification, any reading above 180/120, or the presence of additional cardiovascular risk factors such as diabetes or chronic kidney disease.